First approval of an intracranial stent in Japan
This article was originally published in The Gray Sheet
Executive Summary
Tokyo-based Johnson & Johnson/K.K. Medical Co. announces March 23 that Japan's Ministry of Health, Labor and Welfare has approved J&J/Codman's Enterprise vascularreconstruction device and delivery system. The self-expanding stent is used to treat wide-necked intracranial aneurysms. It marks the first approval for an intracranial stent by MHLW. Last year, J&J moved its central nervous system disorder device unit from its Cordis subsidiary to the Codman & Shurtleff unit (1"The Gray Sheet" Jan. 12, 2009)
You may also be interested in...
Mergers & Acquisitions In Brief
China Medical divests ultrasound biz: China Medical Technologies divests its high-intensity focused ultrasound (HIFU) tumor therapy business to shareholder Chengxuan International for $53.5 million in order to refocus on in vitro diagnostics. Xiaodong Wu, who is both CEO of CMT and owner of Chengxuan, did not take part in deliberations over the sale, which was approved by CMT's independent board members, CMT notes. Announced Dec. 31, the move reflects pressures on the HIFU business from the global financial crisis, stricter regulations on medical equipment by China's State FDA, and the financial burden involved in obtaining U.S. and EU regulatory approvals for HIFU equipment, CMT explains. Beijing-based CMT recently acquired a human papillomavirus genotyping assay for $345 million, which it expects will generate up to $26.5 million in sales this year; the company will use the proceeds from the HIFU sale to further develop its molecular diagnostics business (1"The Gray Sheet" Oct. 13, 2008, p. 8)
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.